MetaVia's DA-1726 Shows Preferential Fat Tissue Distribution in Preclinical Study
Event summary
- Preclinical study shows DA-1726-derived radioactivity is preferentially distributed to adipose tissue, with highest exposure in abdominal, subcutaneous, and brown fat.
- Tissue-to-plasma ratios increased over time, indicating prolonged retention of DA-1726 in tissues relative to plasma.
- Phase 1 study showed 48 mg dose of DA-1726 achieved mean waist circumference reduction of 9.8 cm after 8 weeks.
- 16-week topline data from ongoing 24-week dose-titration study expected in Q4 2026, with 24-week results in Q1 2027.
The big picture
MetaVia's preclinical findings provide mechanistic support for DA-1726's differentiated profile in obesity treatment. The preferential distribution to adipose tissue and prolonged retention align with the drug's once-weekly dosing and observed clinical efficacy. This positions DA-1726 as a potential next-generation obesity therapy, competing with established GLP-1 receptor agonists. The upcoming 16-week and 24-week topline data will be critical in assessing the drug's long-term potential.
What we're watching
- Clinical Efficacy
- Whether longer treatment with DA-1726 can further enhance reductions in waist circumference, weight loss, and other cardiometabolic measures.
- Regulatory Pathway
- The pace at which MetaVia can advance DA-1726 through clinical trials and secure regulatory approval.
- Competitive Positioning
- How DA-1726's differentiated profile and preclinical data will position it against competitors like semaglutide and tirzepatide.
Related topics